Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease. / Ahluwalia, Tarunveer S.; Rönkkö, Teemu K.E.; Eickhoff, Mie K.; Curovic, Viktor Rotbain; Siwy, Justyna; Eder, Susanne; Denicolò, Sara; Mayer, Gert; Mischak, Harald; Rossing, Peter; Persson, Frederik.
I: Kidney International Reports, Bind 9, Nr. 2, 2024, s. 334-346.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease
AU - Ahluwalia, Tarunveer S.
AU - Rönkkö, Teemu K.E.
AU - Eickhoff, Mie K.
AU - Curovic, Viktor Rotbain
AU - Siwy, Justyna
AU - Eder, Susanne
AU - Denicolò, Sara
AU - Mayer, Gert
AU - Mischak, Harald
AU - Rossing, Peter
AU - Persson, Frederik
N1 - Publisher Copyright: © 2023 International Society of Nephrology
PY - 2024
Y1 - 2024
N2 - Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as novel therapeutics to treat diabetic kidney disease (DKD). Although the beneficial effects of SGLT2i have been demonstrated, their target mechanisms on kidney function are unknown. The current study aimed to elucidate these mechanisms by studying SGLT2i-induced changes in the urinary proteome of persons with type 2 diabetes (T2D) and DKD. Methods: A total of 40 participants with T2D were enrolled in a double-blinded randomized cross-over trial at the Steno Diabetes Center Copenhagen, Denmark. They were treated with 10 mg of dapagliflozin for 12 weeks. Thirty-two participants with complete urinary proteomics measures before and after the trial were included. All participants received renin-angiotensin system blockade and had albuminuria, (urine albumin-to-creatinine ratio [UACR] ≥30 mg/g). A type 1 diabetes (T1D) cohort consisting of healthy controls and persons with DKD was included for validation. Urinary proteome changes were analyzed using Wilcoxon signed-rank test. Functional enrichment analysis was conducted to discover affected biological processes. Results: Dapagliflozin treatment significantly (Padjusted < 0.05) affected 36 urinary peptide fragments derived from 19 proteins. Eighteen proteins were correspondingly reflected in the validation cohort. A multifold change in peptide abundance was observed in many proteins (A1BG, urinary albumin [ALB], Caldesmon 1, COLCRNN, heat shock protein 90-β [HSP90AB1], IGLL5, peptidase inhibitor 16 [PI16], prostaglandin-H2-D-isomerase [PTGDS], SERPINA1). These also included urinary biomarkers of kidney fibrosis and function (type I and III collagens and albumin). Biological processes relating to inflammation, wound healing, and kidney fibrosis were enriched. Conclusion: The current study discovers the urinary proteome impacted by the SGLT2i, thereby providing new potential target sites and pathways, especially relating to wound healing and inflammation.
AB - Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as novel therapeutics to treat diabetic kidney disease (DKD). Although the beneficial effects of SGLT2i have been demonstrated, their target mechanisms on kidney function are unknown. The current study aimed to elucidate these mechanisms by studying SGLT2i-induced changes in the urinary proteome of persons with type 2 diabetes (T2D) and DKD. Methods: A total of 40 participants with T2D were enrolled in a double-blinded randomized cross-over trial at the Steno Diabetes Center Copenhagen, Denmark. They were treated with 10 mg of dapagliflozin for 12 weeks. Thirty-two participants with complete urinary proteomics measures before and after the trial were included. All participants received renin-angiotensin system blockade and had albuminuria, (urine albumin-to-creatinine ratio [UACR] ≥30 mg/g). A type 1 diabetes (T1D) cohort consisting of healthy controls and persons with DKD was included for validation. Urinary proteome changes were analyzed using Wilcoxon signed-rank test. Functional enrichment analysis was conducted to discover affected biological processes. Results: Dapagliflozin treatment significantly (Padjusted < 0.05) affected 36 urinary peptide fragments derived from 19 proteins. Eighteen proteins were correspondingly reflected in the validation cohort. A multifold change in peptide abundance was observed in many proteins (A1BG, urinary albumin [ALB], Caldesmon 1, COLCRNN, heat shock protein 90-β [HSP90AB1], IGLL5, peptidase inhibitor 16 [PI16], prostaglandin-H2-D-isomerase [PTGDS], SERPINA1). These also included urinary biomarkers of kidney fibrosis and function (type I and III collagens and albumin). Biological processes relating to inflammation, wound healing, and kidney fibrosis were enriched. Conclusion: The current study discovers the urinary proteome impacted by the SGLT2i, thereby providing new potential target sites and pathways, especially relating to wound healing and inflammation.
KW - dapagliflozin
KW - diabetic kidney disease
KW - randomized controlled trial
KW - SGLT2
KW - sodium-glucose cotransporter 2 inhibitors
KW - urinary proteomics
U2 - 10.1016/j.ekir.2023.11.020
DO - 10.1016/j.ekir.2023.11.020
M3 - Journal article
C2 - 38344728
AN - SCOPUS:85183541312
VL - 9
SP - 334
EP - 346
JO - Kidney International Reports
JF - Kidney International Reports
SN - 2468-0249
IS - 2
ER -
ID: 381719081